Hypercalcemia in malignancies is a frequent complication, mostly affecting patients with solid tumors or multiple myeloma. Calcium elevation is induced by direct bone infiltration of a tumor mass or through calcium liberation from the skeleton by a humoral mediator. The latter mechanism is referred to as humoral hypercalcemia of malignancy (HHM). Frequent mediators of HHM are parathyroid hormone-related peptides (PTHrP). We report a patient with chronic lymphocytic leukemia and hypercalcemia induced by PTHrP. In contrast to solid tumors and myeloma, PTHrP-induced HHM is very rare in low-grad lymphoma including chronic lymphocytic leukemia. Therapeutical approaches consist of cytoreductive treatment and calcium-lowering therapy with bisphosphonates.

Grill V, Maring TJ: Hypercalcemia of malignancy. Rev Endocr Metab Disord 2000;1:253–263.
Mundy GR, Guise TA: Hypercalcemia of malignancy. Am J Med 1997;103:134–145.
Rankin W, Grill V, Martin TJ: Parathyroid hormone-related protein and hypercalcemia. Cancer 1997;80:1564–1571.
Firkin F, Seymour JF, Watson A, Grill V, Martin TJ: Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy. Br J Haematol 1996;94:468–492.
Majumdar G: Incidence and prognostic significance of hypercalcemia in B-cell non-Hodgkin’s lymphoma. J Clin Pathol 2002;55:637–638.
Seymour JF, Gagel RF: Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin’s disease and non-Hodgkin’s lymphomas. Blood 1993;85:1383–1394.
Clines GA, Guise TA: Hypercalcemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005;12:549–583.
Beaudreuil J, Lortholary O, Martin A, Feuillard J, Guillevin L, Raphael M, Casassus P: Hypercalcemia may indicate Richter’s syndrome. Cancer 1997;79:1211–1215.
Minina E, Wenzel HM, Kreschel C, Karp S, Gaffield W, McMahon AP, Vortkamp A: BMP and Ihh/PTHrP signaling interact to coordinate chondrocyte proliferation and differentiation. Development 2001;128:4523–4534.
Wysolmerski JJ, Broadus AE, Zhou J, Fuchs E, Milstone LM, Philbrick WM: Overexpression of parathyroid hormone-related protein in the skin of transgenic mice interferes with hair follicle development. Proc Natl Acad Sci USA 1994;91:1133–1137.
Wysolmerski JJ, Philbrick WM, Dunbar ME, Lanske B, Kronenberg H, Broadus AE: Rescue of the parathyroid hormone-related protein knockout mouse demonstrates that parathyroid hormone-related protein is essential for mammary gland development. Development 1998;125:1285–1294.
Schilling T, Pecherstorfer M, Blind E, Leidig G, Ziegler R, Raue F: Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab 1993;76:801–803.
Southby J, Kissin MW, Danks JA, Haymann JA, Moseley JM, Henderson MA: Immunhistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res 1990;50:7710–7716.
Sato K, Fujii Y, Kasono K, Ozawa M, Imamura H, Kanaji Y, Kurosawa H, Tsushima T, Shizume K: Parathyroid hormone-related protein and interleukin-1 alpha synergistically stimulate bone resorption in vitro and increase the serum calcium concentration in mice in vivo. Endocrinology 1989;124:2172–2178.
Guise TA, Yoneda T, Yates AJP, Mundy GR: The combined effect of tumor-produced parathyroid hormone-related peptide and transforming growth factor enhance hypercalcemia in vivo and bone resorption in vitro. J Clin Endocrinol Metab 1993;77:40–45.
Fukumoto S, Matsumoto T, Ikeda K, Yamashita T, Watanabe T, Yamaguchi K, Kiyokawa T, Takatsuki K, Shibuya N, Ogata E: Clinical evaluation of calcium metabolism in adult T-cell leukemia/lymphoma. Arch Intern Med 1988;148:921–925.
Watanabe T, Yamaguchi K, Takatsuki K, Osame M, Yoshida M: Constitutive expression of parathyroid hormone-related protein gene by the human T-cell leukemia virus type 1 (HTLV-1) tax and HTLV-2 tax proteins. Blood 1993;81:1017–1024.
Fain O, el M’Selmi A, Dosquet C, Meseure D, Lejeune F, Garel JM, Thomas M: Hypercalcemia in B cell chronic lymphocytic leukemia. Br J Haematol 1994;87:856–858.
Lemer D, Esteves C, De Oliveira MS: B-CLL in PLL transformation associated with hypercalcemia. Leuk Lymphoma 1994;12:231–235.
Vlasfeld LT, Pauwels T, Ermens AA, Aarnoudse WH, Ooms HW, Haak HR: Parathyroid-hormone-related protein (PTH-rP) associated hypercalcemia in a patient with an atypical chronic lymphocytic leukaemia. Neth J Med 1999;54:21–26.
Seymour JF, Keating MJ: Parathyroid-hormone-related protein in hypercalcaemia in CLL. Br J Haematol 1995;89:685–686.
Davies SV, Vora J, Wardrop CAJ: Parathyroid hormone related protein (PTHrP) in hypercalcaemia of lymphoproliferative disease. J Clin Pathol 1993;46:188–191.
Schoevaerdts D, Mineur P, Hennaux V, Sibille C: Hypercalcemia, chronic lymphocytic leukaemia and multiple myeloma: uncommon association. Acta Clin Belg 1999;54:217–219.
Schöttker B, Heinz W, Weissinger F, Sözener K, Eck M, Seufen J: Parathyroid hormone-related protein-associated hypercalcemia in a patient with CLL type low grade leukemic B-cell lymphoma. Hematologica 2006;91(suppl 12):ECR45.
Sato K, Onuma E, Yocum RC, Ogata E: Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody. Semin Oncol 2003;5(suppl 16):167–173.
Vassilopoulou-Sellin R, Newman BM, Tylor SH, Ensor JE, Guinee VF: Hypercalcemia of malignancy: incidence in a comprehensive cancer centre. Proc Am Soc Clin Oncol 1991;10:131.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.